



Sri Lanka: Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility

Project Name	Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility								
Project Number	55085-001								
Country	Sri Lanka								
Project Status	Active								
Project Type / Modality of Assistance	Loan								
Source of Funding / Amount	<table border="1"> <tr> <td colspan="2">Loan 4083-SRI: Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility</td> </tr> <tr> <td>Ordinary capital resources</td> <td>US\$ 84.00 million</td> </tr> <tr> <td colspan="2">Loan 4084-SRI: Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility</td> </tr> <tr> <td>Ordinary capital resources</td> <td>US\$ 66.00 million</td> </tr> </table>	Loan 4083-SRI: Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility		Ordinary capital resources	US\$ 84.00 million	Loan 4084-SRI: Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility		Ordinary capital resources	US\$ 66.00 million
Loan 4083-SRI: Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility									
Ordinary capital resources	US\$ 84.00 million								
Loan 4084-SRI: Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility									
Ordinary capital resources	US\$ 66.00 million								
Strategic Agendas	Environmentally sustainable growth Inclusive economic growth Regional integration								
Drivers of Change	Governance and capacity development Partnerships								
Sector / Subsector	Health - Disease control of communicable disease								
Gender Equity and Mainstreaming	Effective gender mainstreaming								
Description	<p>The project will provide the Government of Sri Lanka with immediate and flexible financing to support the national COVID-19 vaccination program through APVAX and the regular country allocation. The APVAX allocation comprises a rapid response component (RRC) to support the purchase of Asian Development Bank (ADB) eligible COVID-19 vaccines, while the project investment component (PIC) financed by the regular country allocation will support strengthening of the vaccination information dissemination and monitoring systems, vaccine transportation capacity, and vaccine-related medical waste management.</p> <p>The project is aligned with the ADB's Strategy 2030 vision for achieving a prosperous, inclusive, resilient, sustainable Asia and the Pacific. The project contributes to addressing remaining nonincome and income poverty and to reducing inequalities, accelerating progress in gender equality, strengthening governance and institutional capacity, fostering regional cooperation and integration, tackling disaster resilience, and enhancing environmental sustainability in Sri Lanka.</p>								
Project Rationale and Linkage to Country/Regional Strategy	<p>Sri Lanka is an island with a population of 21.9 million. The country stands on the cusp of being an upper middle-income country. It was reclassified as a lower middle-income country in July 2020 after being an upper middle-income country for a year based on its classification as of July 2019. The economy entered the global COVID-19 pandemic in 2020 after suffering a series of shocks that slowed growth. The onset of the pandemic came less than 12 months after the April 2019 Easter Sunday terror attacks that severely impacted tourism and growth. Prior to that, a constitutional crisis in late 2018 and droughts in 2016 and 2017 also weighed heavily on the economy. Sri Lanka's gross domestic product (GDP) growth has shown a recent downward trend and averaged 3.7% during 2015-2019 compared to 6.8% during 2010-2014 on the back of a peace dividend and rehabilitation after the end of the civil conflict in 2009. The GDP per capita for 2020 was \$3,682, down from \$3,852 in 2019.</p> <p>Status of the Pandemic. COVID-19 cases were first reported in Sri Lanka in January 2020 and the first wave of COVID-19 was during March-June 2020, the second wave was during September 2020-March 2021, and the ongoing third wave has been going on since 25 April 2021. As of 2 June 2021, Sri Lanka had reported 192,547 confirmed cases and 1,566 deaths. The third wave continues to bring an unprecedented and exponential number of COVID-19 patients to health facilities, with the effective reproduction rate increasing from 0.85 on 1 October 2020 to 1.08 on 2 June 2021. In that period, the number of daily new confirmed cases increased from 0.33 per million people to 135.23 per million people. The reported spread of the new coronavirus variants which are known to be more infectious add to this increasing trend. The Government enforced population-wide and health sector-wide interventions since March 2020 to curtail the spread of the pandemic. To move back towards a sustainable economic growth trajectory from 2021, the Government of Sri Lanka plans to vaccinate 80% of the population as an intervention of utmost priority.</p>								
Impact	Resilience and responsiveness of the health system enhanced to curtail the COVID-19 virus spread; reduce morbidity and mortality; and reduce the negative health, social, and economic effects of the COVID-19 pandemic in Sri Lanka.								
Project Outcome									
Description of Outcome	Priority populations of Sri Lanka vaccinated against COVID-19 as per the NDVP without compromising routine vaccine service and other health services.								
Progress Toward Outcome									
Implementation Progress									
Description of Project Outputs	<p>COVID-19 vaccines delivered.</p> <p>Vaccination information dissemination and monitoring systems strengthened.</p> <p>Capacity of vaccine transport systems expanded</p> <p>Vaccine-related medical waste management strengthened</p>								
Status of Implementation Progress (Outputs, Activities, and Issues)									
Geographical Location	Nation-wide								

Safeguard Categories	
Environment	B
Involuntary Resettlement	C
Indigenous Peoples	C

Summary of Environmental and Social Aspects	
Environmental Aspects	
Involuntary Resettlement	
Indigenous Peoples	
Stakeholder Communication, Participation, and Consultation	
During Project Design	
During Project Implementation	

Business Opportunities	
Consulting Services	Individual consultant selection / firm recruitment (CQS) in conformity with ADB's Procurement Policy (2017, as amended from time to time) and the Procurement Regulations for ADB Borrowers, Goods, Works, Non-consulting and Consulting Services (2017, as amended from time to time).
Procurement	Direct contracting / OCB / RFQ in conformity with ADB's Procurement Policy (2017, as amended from time to time) and the Procurement Regulations for ADB Borrowers, Goods, Works, Non-consulting and Consulting Services (2017, as amended from time to time).

Responsible ADB Officer	Arora, Dinesh
Responsible ADB Department	South Asia Department
Responsible ADB Division	Human and Social Development Division, SARD
Executing Agencies	Ministry of Health Mr. W.M. Piyasena PMU@HSEP.LK Suwasiripaya, No.385, Rev.Baddegama Wimalawansa Thero Mawatha

Timetable	
Concept Clearance	01 Jan 2023
Fact Finding	01 Mar 2021 to 05 Mar 2021
MRM	27 May 2021
Approval	08 Jul 2021
Last Review Mission	-
Last PDS Update	08 Jul 2021

Loan 4083-SRI

Milestones					
Approval	Signing Date	Effectivity Date	Closing		
			Original	Revised	Actual
08 Jul 2021	09 Jul 2021	19 Aug 2021	31 Dec 2024	-	-

Financing Plan		Loan Utilization			
	Total (Amount in US\$ million)	Date	ADB	Others	Net Percentage
Project Cost	95.85	Cumulative Contract Awards			
ADB	84.00	29 Sep 2021	84.00	0.00	100%
Counterpart	11.85	Cumulative Disbursements			
Cofinancing	0.00	29 Sep 2021	0.00	0.00	0%

Loan 4084-SRI

Milestones					
Approval	Signing Date	Effectivity Date	Closing		
			Original	Revised	Actual
08 Jul 2021	09 Jul 2021	19 Aug 2021	31 Dec 2024	-	-

Financing Plan		Loan Utilization			
	Total (Amount in US\$ million)	Date	ADB	Others	Net Percentage
Project Cost	66.00	Cumulative Contract Awards			

ADB		66.00	29 Sep 2021	0.00	0.00	0%
Counterpart		0.00	Cumulative Disbursements			
Cofinancing		0.00	29 Sep 2021	0.00	0.00	0%

Project Page	https://www.adb.org/projects/55085-001/main
Request for Information	http://www.adb.org/forms/request-information-form?subject=55085-001
Date Generated	03 November 2021

ADB provides the information contained in this project data sheet (PDS) solely as a resource for its users without any form of assurance. Whilst ADB tries to provide high quality content, the information are provided "as is" without warranty of any kind, either express or implied, including without limitation warranties of merchantability, fitness for a particular purpose, and non-infringement. ADB specifically does not make any warranties or representations as to the accuracy or completeness of any such information.